You have read all your free articles, to continue reading subscribe to read the rest of this content.
Karolinska Development has announced that CEO Torbjörn Bjerke leaves the company. Bjerke will be replaced by Klaus Wilgenbus until a new permanent CEO has been appointed. Torbjörn Bjerke leaves his position as CEO on September 30, 2014, and Klaus Wilgenbus steps down from his Board positioAlready a subscriber Login You have read all your free…
Three members of the company's Board, Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl, has decided to step down from the Board with immediate effect. Following the decisions to discontinue the PARADIGME study for Betalutin, restructure the company and appoint Carnegie Investment Bank toAlready a subscriber Login You have read…
The company has recruited Dr. Kim Arvid Nielsen as new CEO, taking office on April 6, 2021. He has extensive experience in business development, investor relations and drug development from leading positions in both small and large pharmaceutical companies. At the same time, Follicum is establAlready a subscriber Login You…
The company is strengthening its presence in the US market through a recruitment of Dr. Joshua J. Schmidt as Business Development Director at SenzaGen Inc. The appointment represents a further expansion of the company's commercial organization and an increasing focus on establishing collaborationAlready a subscriber Login You have read all…
